Cite
MLA Citation
Eric Lawitz et al.. “Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.” Lancet, vol. 385, no. 9973, 2015, pp. 1075–1086. http://access.bl.uk/ark:/81055/vdc_100042507111.0x00004a